Scinai Immunotherapeutics (SCNI) Short term Debt (2021 - 2025)

Scinai Immunotherapeutics has disclosed Short term Debt across 3 years of filings, most recently posting -$7.2 million for Q4 2025.

• In Q4 2025, Short term Debt changed N/A year-over-year to -$7.2 million; the TTM figure through Dec 2025 stood at -$7.2 million (changed N/A YoY), while the FY2025 annual figure was -$7.2 million, changed N/A from the prior year.
• Short term Debt came in at -$7.2 million for Q4 2025 at Scinai Immunotherapeutics, down from $382000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $382000.0 in Q4 2022 to a low of -$7.2 million in Q4 2025.
• Average Short term Debt over 3 years is -$2.2 million, with a median of $375000.0 recorded in 2021.
• The largest YoY upside for Short term Debt was 1.87% in 2022 against a maximum downside of 1.87% in 2022.
• Over 3 years, Short term Debt stood at $375000.0 in 2021, then increased by 1.87% to $382000.0 in 2022, then slumped by 1997.12% to -$7.2 million in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were -$7.2 million in Q4 2025, $382000.0 in Q4 2022, and $375000.0 in Q4 2021.